• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

CATEGORIES

  • 19
  • 11
  • 2
  • 1
  • 1

PRICE

0
0
19
23

PUBLISHED

0
2
17
23

PRODUCT TYPE

23

Search "Ohr Pharmaceutical, Inc.-Therapeutic Competitors" returned 23 results.

Cancer Cachexia - Pipeline Review, H2 2014

Cancer Cachexia - Pipeline Review, H2 2014 Summary This, ‘Cancer Cachexia - Pipeline Review, H2 2014’, provides an overview of the Cancer Cachexia’s therapeutic pipeline. This report provides comprehensive...

September 2014
FROM

Diabetic Macular Edema - Pipeline Review, H2 2014

Diabetic Macular Edema - Pipeline Review, H2 2014 Summary This, ‘Diabetic Macular Edema - Pipeline Review, H2 2014’, provides an overview of the Diabetic Macular Edema’s therapeutic pipeline. This...

October 2014
FROM

Retinal Vein Occlusion - Pipeline Review, H1 2015

Retinal Vein Occlusion - Pipeline Review, H1 2015 Summary This, ‘Retinal Vein Occlusion - Pipeline Review, H1 2015’, provides an overview of the Retinal Vein Occlusion’s therapeutic pipeline. This...

May 2015
FROM

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2015

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2015 Summary This, ‘Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2015’, provides an overview of the Proliferative Diabetic...

March 2015
FROM

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2014

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2014 Summary This, ‘Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2014’, provides an overview of the Proliferative Diabetic...

October 2014
FROM

Cancer Cachexia - Pipeline Review, H1 2014

Cancer Cachexia - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Cancer Cachexia - Pipeline Review, H1 2014’, provides an overview of the Cancer Cachexia’s therapeutic pipeline. This...

June 2014
FROM

Retinal Vein Occlusion - Pipeline Review, H2 2014

Retinal Vein Occlusion - Pipeline Review, H2 2014 Summary This, ‘Retinal Vein Occlusion - Pipeline Review, H2 2014’, provides an overview of the Retinal Vein Occlusion’s therapeutic pipeline. This...

August 2014
FROM

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014’, provides...

June 2014
FROM
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2014 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2014 - Product Thumbnail Image

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2014

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2014 Summary This, ‘Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2014’, provides an overview of...

November 2014
FROM

Ovarian Cancer - Pipeline Review, H2 2014

Ovarian Cancer - Pipeline Review, H2 2014 Summary This, ‘Ovarian Cancer - Pipeline Review, H2 2014’, provides an overview of the Ovarian Cancer’s therapeutic pipeline. This report provides comprehensive...

October 2014
FROM

Ovarian Cancer - Pipeline Review, H1 2014

Ovarian Cancer - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Ovarian Cancer - Pipeline Review, H1 2014’, provides an overview of the Ovarian Cancer’s therapeutic pipeline. This report...

April 2014
FROM

Allergic Conjunctivitis - Pipeline Review, H1 2015

Allergic Conjunctivitis - Pipeline Review, H1 2015 Summary This, ‘Allergic Conjunctivitis - Pipeline Review, H1 2015’, provides an overview of the Allergic Conjunctivitis’s therapeutic pipeline. This...

April 2015
FROM

Glaucoma - Pipeline Review, H2 2014

Glaucoma - Pipeline Review, H2 2014 Summary This, ‘Glaucoma - Pipeline Review, H2 2014’, provides an overview of the Glaucoma’s therapeutic pipeline. This report provides comprehensive information...

July 2014
FROM

Allergic Conjunctivitis - Pipeline Review, H2 2014

Allergic Conjunctivitis - Pipeline Review, H2 2014 Summary This, ‘Allergic Conjunctivitis - Pipeline Review, H2 2014’, provides an overview of the Allergic Conjunctivitis’s therapeutic pipeline. This...

August 2014
FROM

Rheumatoid Arthritis - Pipeline Review, H1 2014

Rheumatoid Arthritis - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Rheumatoid Arthritis - Pipeline Review, H1 2014’, provides an overview of the Rheumatoid Arthritis’s therapeutic pipeline. This...

February 2014
FROM

Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate

Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate Summary GBI Research, the leading business intelligence provider, has released its latest research,...

October 2011
FROM

Diabetic Retinopathy - Pipeline Review, H2 2014

Diabetic Retinopathy - Pipeline Review, H2 2014 Summary This, ‘Diabetic Retinopathy - Pipeline Review, H2 2014’, provides an overview of the Diabetic Retinopathy’s therapeutic pipeline. This report...

September 2014
FROM

Cachexia - Pipeline Review, H1 2014

Cachexia - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Cachexia - Pipeline Review, H1 2014’, provides an overview of the Cachexia’s therapeutic pipeline. This report provides comprehensive...

March 2014
FROM

Cachexia - Pipeline Review, H2 2014

Cachexia - Pipeline Review, H2 2014 Summary This, ‘Cachexia - Pipeline Review, H2 2014’, provides an overview of the Cachexia’s therapeutic pipeline. This report provides comprehensive information...

August 2014
FROM

Glaucoma - Pipeline Review, H1 2015

Glaucoma - Pipeline Review, H1 2015 Summary This, ‘Glaucoma - Pipeline Review, H1 2015’, provides an overview of the Glaucoma’s therapeutic pipeline. This report provides comprehensive information...

January 2015
FROM
Loading Indicator

Our Clients

Walgreen's Company Elanco Global Nu Skin Enterprises Kemin Industries, Inc. Suan Farma Inc. Metagenics, Inc.